Free Newsletter
Novartis blueprints $36M vaccine research lab in NC
Novartis ($NVS) has blueprinted plans for a $36 million vaccine research lab in Holly Springs, NC, and plans to fill about 100 high-paying jobs to staff the addition.
The expansion follows the construction of Novartis' $600 million vaccine manufacturing plant, which opened last year. This new facility will include vaccine manufacturing capacity to produce experimental vaccines for research studies.
Novartis, which landed a 167-acre site in Holly Springs, is creating a vaccine research and manufacturing hub in the area alongside Merck ($MRK) and Pfizer ($PFE).
- here's the story from the News & Observer
Related Articles:
Novartis vax division booms as demand spikes
N.C. town welcomes Novartis plant
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
More Research Reports >>
SHARE
WITH: